Adavosertib not checked
AstraZeneca · MK-1775 · AZD 1775
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.”In the company’s words, NCT03330847 on ClinicalTrials.gov
- Main trialPhase 2
- “This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib…”In the company’s words, NCT03330847 on ClinicalTrials.gov
- Other names
- MK-1775 · AZD 1775
Other drugs for Metastatic Triple Negative Breast Cancer
- PembrolizumabMerck & Co. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Sacituzumab govitecanGilead (Kite) · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
- ESG401Qilu Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 13 Nov 2020 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | |
| Phase 1Active, not recruiting | 18 Mar 2020 | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | |
| Phase 2Completed | 8 Aug 2016 | A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | |
| Phase 2Completed | 13 Dec 2018 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |
| Phase 2Completed | 22 Jun 2020 | A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | |
| Phase 2Completed | 23 May 2022 | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma | |
| Phase 1/2Terminated | 13 Jun 2011 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | |
| Phase 1Terminated | 15 Jun 2011 | A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005 | |
| Phase 1Completed | 6 Jan 2014 | A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001) | |
| Phase 1Completed | 25 Jan 2018 | Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | |
| Phase 1Completed | 26 Apr 2018 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | |
| Phase 1Completed | 22 Apr 2019 | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | |
| Phase 1Completed | 22 Sep 2021 | Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours | |
| Phase 1Terminated | 16 Nov 2021 | Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib | |
| Phase 1Terminated | 21 Apr 2022 | A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | |
| Phase 1Terminated | 1 Jun 2022 | A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026